A New Formulation of Dihydroergotamine (DHE) is Effective for Sustaining Relief in the Acute Treatment of Migraine


Home \| About Dr. Robbins \| Archived Articles \| Headache Books \| Topic Index

Back to List

Title:

Author:
Date:
Source:

A New Formulation of Dihydroergotamine (DHE) is
Effective for Sustaining Relief in the Acute
Treatment of Migraine
Frishberg B.J.
Posted July 2003
Presented at: 45th Annual Scientific Meeting
American Headache Society
June 19-22, 2003; Chicago, Illinois

Objectives: To compare the safety and efficacy of a single subcutaneous dose of DHE with matching placebo in the acute treatment of migraine attacks.

Conclusions: The MT 300 formulation of DHE is well-tolerated and effective for the sustained relief of migraine pain and associated symptoms, particularly in patients with severe pain. Patients requiring parenteral treatment of migraines may benefit from this new dosage form that combines the proven efficacy of DHE with packaging that allows the product to be used more easily by patients.

Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index